Recent News

• 03.27.2026 - Quantum Biopharma Provides Corporate Update
• 03.27.2026 - Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status
• 03.26.2026 - Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis
• 03.23.2026 - Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd
• 03.20.2026 - Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering
• 03.11.2026 - Quantum BioPharma Provides Corporate Update
• 03.10.2026 - Quantum BioPharma Provides Corporate Update
• 12.23.2025 - Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
• 12.22.2025 - World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Recent Filings

• 03.27.2026 - EX-99.1 EX-99.1
• 03.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.26.2026 - EX-99.1 EX-99.1
• 03.26.2026 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.23.2026 - EX-99.1 EX-99.1
• 03.23.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.03.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.23.2025 - EX-99.1 EX-99.1
• 12.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]